┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0593
  SLUG ................ /gsk-paroxetine-publication-rights-ghostwriting
  STATUS .............. ACTIVE
  FILED ............... 2026-06-22 03:15 UTC
  LAST ANNOTATED ...... 2026-06-22 03:15 UTC
  CLAIMS ON FILE ...... 6
  MEAN TAG CONFIDENCE . 0.89
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

GSK Paroxetine Trials: Publication Rights and Ghostwriting Agreements

SUMMARY

This dossier investigates the availability of contractual agreements between GlaxoSmithKline (GSK) and individual researchers, such as Martin Keller, involved in paroxetine clinical trials, particularly concerning publication rights and ghostwriting. Allegations of ghostwriting in GSK's Study 329, which evaluated paroxetine (Paxil/Seroxat) for adolescent depression, surfaced following legal challenges that led to the public release of internal company documents. While GSK maintains a public study register and professes transparency, the specific contractual details governing individual researchers' publication rights or ghostwriting arrangements are not readily accessible through these public portals.

Critiques of Study 329 highlight that the original published findings, which claimed efficacy for paroxetine, contradicted later analyses of the raw data. These later analyses indicated a lack of efficacy and an association with harms in adolescents. The role of medical communications companies in drafting manuscripts for industry-sponsored trials has been raised in this context, suggesting that primary investigators may not have had full control over the published output or may have been contractually limited.

While general information about clinical trials is available, detailed contractual agreements between pharmaceutical companies and individual investigators are typically private documents. The question remains whether any such agreements, particularly those outlining publication control or ghostwriting, have been made publicly available through court orders or other means, beyond general funding acknowledgments.

STRONGEST CASE FOR

The pharmaceutical industry, like many sectors, operates with proprietary contracts to protect intellectual property and manage research output. While institutions receive funding, specific contractual agreements with individual researchers, including those related to publication rights, are private business matters. These contracts are not typically released into the public domain unless compelled by specific legal processes, such as discovery in litigation. GSK has made efforts towards transparency through its study register, providing general information about trials and some documents, which suggests a commitment to public disclosure within established industry norms.

STRONGEST CASE AGAINST

The lack of public access to contractual agreements between pharmaceutical companies and individual researchers, especially regarding publication rights, creates a significant transparency gap. This opacity can facilitate ghostwriting and influence the reporting of trial results, potentially obscuring negative findings or overstating benefits. The case of GSK's Study 329, where re-analysis of raw data contradicted the published findings and highlighted the involvement of medical communications companies, demonstrates the potential for such private agreements to undermine scientific integrity and public health. For genuine transparency and accountability, especially in trials affecting public health, these contractual details should be made publicly accessible.

CLAIMS

  1. CORROBORATEDCONF 0.90

    GSK contracted Scientific Therapeutic Initiatives (STI), a medical communications company, to prepare the manuscript for a paroxetine trial.

    — attributed to: A 2010 research paper by S.G. McHenry and other sources

    • https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
  2. VERIFIEDCONF 0.95

    The institutions of the authors involved in the original 2001 paroxetine study (Study 329) received funding from GlaxoSmithKline.

    — attributed to: A 2016 BMJ response attachment regarding competing interests

    • https://www.bmj.com/sites/default/files/response_attachments/2016/01/Competing%20interests%20Keller%20et%20al.pdf
  3. VERIFIEDCONF 0.90

    Relevant documents concerning GSK's paroxetine trials were released into the public domain after a legal challenge by Baum Hedlund against GSK's claim to confidentiality.

    — attributed to: A 2008 academic paper by Lisa McHenry

    • https://www.csun.edu/~lmchenry/documents/ghostwrite329.pdf
  4. VERIFIEDCONF 0.98

    The GSK Study Register is an online portal that provides information on clinical trials, including purpose, design, locations, eligibility, and links to some clinical trial documents.

    — attributed to: GSK's official website

    • https://www.gsk-studyregister.com/
    • https://www.gsk.com/en-gb/innovation/trials/data-transparency
  5. SINGLE-SOURCECONF 0.70

    Contractual agreements between pharmaceutical companies and individual researchers are generally not publicly available, as they are considered private contracts.

    — attributed to: Reddit forum discussion

    • https://www.reddit.com/r/books/comments/1xrjvc/is_there_a_place_to_see_anyall_contractual/
  6. CORROBORATEDCONF 0.90

    Re-analysis of GSK's original data for Study 329 indicates that paroxetine (Paxil) was ineffective and harmful for adolescents, contrary to GSK's initial publication.

    — attributed to: A 2015 re-analysis published in the BMJ, referenced in a Reddit discussion

    • https://www.reddit.com/r/science/comments/3l8r8l/restoring_study_329_efficacy_and_harms_of/

TIMELINE

  • 1990sGSK conducts Study 329, an eight-week, placebo-controlled, double-blind randomized clinical trial of paroxetine in adolescents with depression. [src]
  • 2001Original results of Study 329 published in the Journal of the American Academy of Child and Adolescent Psychiatry, claiming efficacy for paroxetine. [src]
  • 2008-07-01Documents relevant to GSK's paroxetine trials are released into the public domain following a legal challenge by Baum Hedlund. [src]
  • 2010Research suggests GSK contracted Scientific Therapeutic Initiatives (STI) for manuscript preparation related to trials. [src]
  • 2015A re-analysis of GSK's original data for Study 329 is published, concluding that paroxetine was ineffective and potentially harmful for adolescents. [src]
  • 2016-01A BMJ response attachment acknowledges that author institutions received funding from GSK for Study 329. [src]

ENTITIES

  • ORG GlaxoSmithKline (GSK) — Pharmaceutical company, sponsor of paroxetine trials
  • PERSON Martin Keller — Individual researcher involved in paroxetine trials, lead author of Study 329
  • ORG Scientific Therapeutic Initiatives (STI) — Medical communications company contracted by GSK for manuscript preparation
  • ORG Paroxetine (Paxil/Seroxat) — Antidepressant drug, subject of the clinical trials
  • ORG Baum Hedlund — Law firm that challenged GSK's confidentiality claims
  • EVENT Study 329 — Clinical trial of paroxetine in adolescents with major depression
  • ORG Journal of the American Academy of Child and Adolescent Psychiatry — Publication venue for the original Study 329 results

OPEN QUESTIONS — PENDING LEADS

  • Have specific contractual agreements between GSK and Martin Keller, or other individual researchers involved in Study 329, detailing publication rights or ghostwriting arrangements, been made public through court discovery or other means?
  • Which specific legal cases or challenges by Baum Hedlund led to the release of GSK documents, and what types of documents were included in the public domain?
  • Are there any publicly disclosed internal GSK policies or guidelines from the late 1990s/early 2000s concerning authors' control over publications for company-sponsored trials?
  • What is the full scope of services provided by Scientific Therapeutic Initiatives (STI) to GSK in relation to paroxetine trials, beyond manuscript preparation?
  • Do any declassified or legally compelled documents from Study 329 explicitly mention ghostwriting clauses or restrictions on researchers' independent analysis and publication?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
    GSK contracted a medical communications company, Scientific Therapeutic Initiatives (STI), to prepare the manuscript.
  2. [WEB] https://www.bmj.com/sites/default/files/response_attachments/2016/01/Competing%20interests%20Keller%20et%20al.pdf [archived]
    "All of the author's institutions received funding from Glaxo-Smith-Kline to conduct the original "All of the author's institutions received funding from Glaxo-Smith-Kline to conduct the original study, published in 2001 in the Journal of the American Academy of Child and Adolesc…
  3. [WEB] https://www.csun.edu/~lmchenry/documents/ghostwrite329.pdf [archived]
    1 Jul 2008 · The relevant documents were released into the public domain after Baum Hedlund challenged GSK's claim to confidentiality by the Trade Secrets ...
  4. [WEB] https://www.gsk-studyregister.com/ [archived]
    The GSK study register provides information on existing vaccines and medicines clinical trials such as the purpose, design, locations and eligibility criteria for participating, in addition to links to clinical trial documents that are currently available. Please see other public…
  5. [WEB] https://davidhealy.org/oneill-oneill-and-frontiers-psychiatry/
    12 Oct 2020 · there is no access to the data from clinical trials. GSK's Study 329 part in future studies. research studies is publicly available for the ...
  6. [WEB] https://www.gsk.com/en-gb/innovation/trials/data-transparency [archived]
    The GSK Study Register is an online portal where anyone can access information about the clinical research we carry out on our existing medicines and vaccines. We were the first pharmaceutical company to make this information available online. As part of our commitment to transpa…
  7. [WEB] https://lawscholars.luc.edu/files/40492960/Avoiding_the_TRIPS_Trap.pdf
    Researchers then found that Paxil failed to show any efficacy for major depression in adolescents and was instead associated with harms contrary to the ...
  8. [WEB] https://www.gsk.com/en-gb/innovation/trials/ [archived]
    Find out about our clinical trials process, how we work with doctors and volunteers and how to become a research volunteer
  9. [REDDIT] https://www.reddit.com/r/biotech/comments/19dwqi6/opinion_on_gsk/
    News about any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use. | Or we can talk about career advice. Whatever.
  10. [REDDIT] https://www.reddit.com/r/clinicalresearch/comments/1dfcyvp/can_trial_researchers_tell_if_potential/
    Can trial researchers tell if potential participants are in other trials? Would a trial researcher at the NIH have access to data regarding someone's participation in other trials? Or is that data private?
  11. [REDDIT] https://www.reddit.com/r/biotech/comments/1c79ark/is_there_a_publically_avaialable_way_to_see_which/
    Is this information publicly available? Is there a way to deduce this information from the clinicaltrials.gov website, such as all phase? Answer *: Thank you for writing the Division of Drug Information in the FDA's Center for Drug Evaluation and Research.* We cannot acknowledge …
  12. [REDDIT] https://www.reddit.com/r/science/comments/3l8r8l/restoring_study_329_efficacy_and_harms_of/ [archived]
    Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. A review of GSK's original data shows that contrary to GSK's publication Paxil is ineffective and harmful when taken by adolescents.
  13. [REDDIT] https://www.reddit.com/r/EARONS/comments/8l4feg/great_new_web_site_specifically_for_gsk_arrest/
    Posted by u/[Deleted Account] - 78 votes and 16 comments
  14. [REDDIT] https://www.reddit.com/r/books/comments/1xrjvc/is_there_a_place_to_see_anyall_contractual/ [archived]
    I don't think contractual agreements are going to be publicly available. If the publishing company is publicly traded, the information might be buried in financial statements. Otherwise, the contractual agreement is a private contract between two parties.
  15. [REDDIT] https://www.reddit.com/r/Open_Access_tracking/comments/q7kotc/open_access_agreements_expand_opportunities_for/ [archived]
    747 subscribers in the Open_Access_tracking community. Federating posts shared by the Open Access Tracking Project.
  16. [REDDIT] https://www.reddit.com/r/AskAcademia/comments/15pmi35/what_do_you_think_about_independent_researchers/ [archived]
    The issue with independent researchers is that it's where a lot of cranks come into my field—either no higher education at all, or in a wildly different field which is disappointingly often engineering or maths, and it leads to wildly inaccurate claims because they don't understa…

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…GSK Paroxetine Trials: Publication Rights and Ghostwriting AgreementsGSK PAROXETINE TRIALS: PUBL…THIS FILESHARES-EVENT